MBIO vs. QTTB, LPCN, CING, MTEX, GELS, CARM, MRKR, CTXR, RVPH, and PMN
Should you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Q32 Bio (QTTB), Lipocine (LPCN), Cingulate (CING), Mannatech (MTEX), Gelteq (GELS), Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.
Mustang Bio vs. Its Competitors
Mustang Bio (NASDAQ:MBIO) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.
10.0% of Mustang Bio shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 0.2% of Mustang Bio shares are owned by insiders. Comparatively, 40.0% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Mustang Bio and Mustang Bio both had 2 articles in the media. Mustang Bio's average media sentiment score of 0.25 beat Q32 Bio's score of 0.00 indicating that Mustang Bio is being referred to more favorably in the media.
Mustang Bio has higher earnings, but lower revenue than Q32 Bio. Q32 Bio is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.
Q32 Bio has a consensus target price of $12.17, indicating a potential upside of 744.91%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts plainly believe Q32 Bio is more favorable than Mustang Bio.
Mustang Bio's return on equity of 0.00% beat Q32 Bio's return on equity.
Mustang Bio has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500.
Summary
Q32 Bio beats Mustang Bio on 8 of the 13 factors compared between the two stocks.
Get Mustang Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mustang Bio Competitors List
Related Companies and Tools
This page (NASDAQ:MBIO) was last updated on 7/3/2025 by MarketBeat.com Staff
